Related Articles
China Approves Norovirus Vaccine for Clinical Trial
Jun 05, 2019
Chinese authorities have greenlit a clinical trial for the world's first tetravalent vaccine against norovirus, the most common cause of viral gastroenteritis. The vaccine, after four years of development, can theoretically prevent 80 to 90 percent of norovirus infections...
Scientists Obtain Clinical Trial Approval of Recombinant Chicken α-interferon Biological Products
Nov 16, 2017
On September 30, 2017, Prof. LIU Wenjun's lab at the Institute of Microbiology of Chinese Academy of Sciences made a joint declaration with Qingdao Vland Biological Products Co., Ltd., Qingdao National Animal Protection Engineering Technology Research Center Co., Ltd., et...
China Approves Norovirus Vaccine for Clinical Trial
Jun 05, 2019
Chinese authorities have greenlit a clinical trial for the world's first tetravalent vaccine against norovirus, the most common cause of viral gastroenteritis. The vaccine, after four years of development, can theoretically prevent 80 to 90 percent of ...
Scientists Obtain Clinical Trial Approval of Recombinant Chicken α-interferon Biological Products
Nov 16, 2017
On September 30, 2017, Prof. LIU Wenjun's lab at the Institute of Microbiology of Chinese Academy of Sciences made a joint declaration with Qingdao Vland Biological Products Co., Ltd., Qingdao National Animal Protection Engineering Technology Research ...
Pynegabine, a First Class Anti-epileptic Drug Targeting KCNQ Potassium Channel Approved for Clinical Study
Dec 05, 2018
Recently, a first class new anti-epileptic drug, pynegabine tablet, developed by Dr. NAN Fajun's and Dr. GAO Zhaobing's groups at the Shanghai Institute of Materia Medica of Chinese Academy of Sciences received the approval of State Food and Drug Admin...